Entrez Gene

General information | Literature | Expression | Regulation | Variant | Interaction

Basic Information
Gene ID	1636
Name	ACE
Synonym	ACE1\|CD143\|DCP\|DCP1\|ICH\|MVCD3;angiotensin I converting enzyme (peptidyl-dipeptidase A) 1;ACE;angiotensin I converting enzyme (peptidyl-dipeptidase A) 1
Definition	CD143 antigen\|angiotensin I converting enzyme peptidyl-dipeptidase A 1 transcript\|angiotensin converting enzyme, somatic isoform\|angiotensin-converting enzyme\|carboxycathepsin\|dipeptidyl carboxypeptidase 1\|dipeptidyl carboxypeptidase I\|kininase II\|peptida
Position	17q23.3
Gene Type	protein-coding
PAH Type	Description
PAH	Deletion polymorphisms in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease.
PAH	Association between the angiotensin-converting enzyme gene polymorphisms and tissue oxygenation during exercise in patients with COPD.
PAH	Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension.
PAH	Angiotensin-converting enzyme gene does not contribute to genetic susceptibility to systemic sclerosis in European Caucasians.
PAH	Polymorphism in the angiotensin II type 1 receptor (AGTR1) is associated with age at diagnosis in pulmonary arterial hypertension.
	More detail of all Human literatures about ACE
Pathways and Diseases
Pathway	Chagas disease;KEGG PATHWAY;hsa05142
Pathway	Hypertrophic cardiomyopathy (HCM);KEGG PATHWAY;hsa05410
Pathway	Renin-angiotensin system;KEGG PATHWAY;hsa04614
Disease	cognitive impairment;GAD
Disease	Premature birth;FunDO
Disease	obstetric cholestasis;GAD
Disease	Cardiovascular disease;FunDO
Disease	SARS, progression of;OMIM
Disease	polydipsia;GAD
Disease	coronary heart disease;GAD
Disease	plasma antigen levels of plasminogen activator inhibitor-1;GAD
Disease	diabetic nephropathy and retinopathy.;GAD
Disease	non-ST-elevation acute coronary syndromes;GAD
Disease	cardiac death;GAD
Disease	Psoriasis;FunDO
Disease	Vascular dementia;FunDO
Disease	polymetabolic syndrome;GAD
Disease	DEVELOPMENTAL;GAD
Disease	Depression;FunDO
Disease	Metabolism disease;FunDO
Disease	longevity;GAD
Disease	early onset ischemic heart disease.;GAD
Disease	IMMUNE;GAD
Disease	Parkinson's disease;GAD
Disease	bleeding complications;GAD
Disease	Alzheimer disease, susceptibility to;OMIM
Disease	carotid arterial wall thickness;GAD
Disease	Colon cancer;FunDO
Disease	elevated ACE;GAD
Disease	PSYCH;GAD
Disease	creatinine;GAD
Disease	Bronchopulmonary dysplasia;FunDO
Disease	Subacute sclerosing panencephalitis;FunDO
Disease	Heart Failure;GAD
Disease	Age-associated memory impairment;GAD
Disease	REPRODUCTION;GAD
Disease	Hypertension;FunDO
Disease	ARDS;GAD
Disease	insulin sensitivity;GAD
Disease	athletic performance;GAD
Disease	anemia C-reactive protein;GAD
Disease	left ventricular hypertrophy;GAD
Disease	affective disorder;GAD
Disease	carotid and femoral artery stiffness;GAD
Disease	Hyperhomocysteinemia;FunDO
Disease	Infectious lung disease;FunDO
Disease	Lupus vulgaris;FunDO
Disease	serum ACE concentration and CAD;GAD
Disease	sarcoidosis;GAD
Disease	Transient hypertension of pregnancy;FunDO
Disease	renal disease;GAD
Disease	Essential Hypertension;GAD
Disease	metabolic syndrome;GAD
Disease	Connective tissue disease;FunDO
Disease	Type 2 Diabetes Mellitus;GAD
Disease	myocardial infarct;GAD
Disease	Myocardial Ischemia;GAD
Disease	polycystic kidney disease;GAD
Disease	Ankylosing spondylitis;FunDO
Disease	Tobacco Use Disorder;GAD
Disease	Lupus erythematosus;FunDO
Disease	insulin left ventricular mass;GAD
Disease	pregnancy loss, recurrent;GAD
Disease	heart disease;GAD
Disease	Respiratory distress syndrome;FunDO
Disease	cardiovascular;GAD
Disease	Migraine;FunDO
Disease	Liver cancer;FunDO
Disease	left ventricular mass;GAD
Disease	Ulcerative colitis;FunDO
Disease	postprandial hyperglycaemia;GAD
Disease	bipolar affective disorder;GAD
Disease	Mucocutaneous lymph node syndrome;FunDO
Disease	hypertension;GAD
Disease	stroke, ischemic;GAD
Disease	Dermatitis;FunDO
Disease	Chronic rejection of renal transplant;FunDO
Disease	nephroangiosclerosis;GAD
Disease	atherosclerosis, coronary;GAD
Disease	kidney transplant;GAD
Disease	renal disease, end stage;GAD
Disease	esophageal varices;GAD
Disease	cardiovascular disease;GAD
Disease	ACE activity;GAD
Disease	increased vascular reactivity;GAD
Disease	Systemic infection;FunDO
Disease	Thromboembolism;GAD
Disease	lipid profiles;GAD
Disease	Kidney disease;FunDO
Disease	carotid wall thickening;GAD
Disease	preeclampsia;GAD
Disease	coronary atherosclerosis;GAD
Disease	Insulin Resistance;GAD
Disease	diabetes, type 1;GAD
Disease	systemic sclerosis;GAD
Disease	coronary artery disease and myocardial infarction;GAD
Disease	cerebral atherosclerosis;GAD
Disease	Kidney Failure, Chronic;GAD
Disease	Endometrial cancer;FunDO
Disease	suicide;GAD
Disease	NORMALVARIATION;GAD
Disease	hypertension, pregnancy induced;GAD
Disease	End- Stage Renal Disease (ESRD);GAD
Disease	antiproteinuric effect of angiotensin I-converting enzyme inhibitors;GAD
Disease	Behcet syndrome;FunDO
Disease	nephropathy, diabetic;GAD
Disease	IGA glomerulonephritis;FunDO
Disease	COPD;GAD
Disease	schizophrenia;GAD
Disease	Heart disease;FunDO
Disease	chronic obstructive pulmonary disease/COPD;GAD
Disease	Allergies and autoimmune diseases;KEGG DISEASE
Disease	ruptured intracranial aneurysms;GAD
Disease	heart rate variability;GAD
Disease	Arthritis;FunDO
Disease	proliferative diabetic retinopathy;GAD
Disease	Atrial Fibrillation;GAD
Disease	endothelial dysfunction in normal humans.;GAD
Disease	Renal tubular dysgenesis;OMIM
Disease	congenital anomalies;GAD
Disease	Macular degeneration;FunDO
Disease	PMV after CABG;GAD
Disease	early onset of ESRF in PKD1 adult polycystic kidney disease;GAD
Disease	lupus erythematosus;GAD
Disease	Asthma;FunDO
Disease	angiotensin-converting enzyme inhibitor-related cough;GAD
Disease	Ischemia;GAD
Disease	Aortic atherosclerosis in diabetes mellitus;GAD
Disease	AGING;GAD
Disease	ACEI-related cough;GAD
Disease	Esophagus cancer;FunDO
Disease	Neoplasm metastasis;FunDO
Disease	Hypoglycemia;FunDO
Disease	reflux nephropathy;GAD
Disease	Systemic Lupus Erythematosus (SLE);GAD
Disease	Prostate cancer;FunDO
Disease	Chronic fatigue syndrome;FunDO
Disease	Anemia;FunDO
Disease	Leukemia;FunDO
Disease	PHARMACOGENOMIC;GAD
Disease	myotonic dystrophy;GAD
Disease	METABOLIC;GAD
Disease	albuminuria hypertension;GAD
Disease	Allograft rejection;KEGG DISEASE;H00083
Disease	restenosis;GAD
Disease	elevated fasting blood glucose levels;GAD
Disease	circulating levels of plasminogen activator inhibitor-1;GAD
Disease	diabetes, type 2;GAD
Disease	Fibroid tumor;FunDO
Disease	Coronary Artery Disease;GAD
Disease	alcoholism;GAD
Disease	CARDIOVASCULAR;GAD
Disease	Schizophrenia;FunDO
Disease	Exercise-induced changes in insulin;GAD
Disease	Myocardial infarction, susceptibility to;OMIM
Disease	Microvascular complications of diabetes 3;OMIM
Disease	Polycythemia;FunDO
Disease	Chronic obstructive airway disease;FunDO
Disease	posttransplantation erythrocytosis;GAD
Disease	protein excretion, urinary;GAD
Disease	blood pressure, arterial;GAD
Disease	Angiotensin I-converting enzyme, benign serum increase;OMIM
Disease	carotid atherosclerosis;GAD
Disease	Cough;GAD
Disease	IgA nephropathy;GAD
Disease	Immune system diseases;KEGG DISEASE
Disease	Obesity;FunDO
Disease	coronary heart disease in non-insulin-dependent diabetic;GAD
Disease	Atherosclerosis;GAD
Disease	diabetic nephropathy;GAD
Disease	Thrombophilia;FunDO
Disease	Angiotensin-converting enzyme activity;NHGRI
Disease	Alzheimer's disease;GAD
Disease	angiotensin-converting enzyme genotype;GAD
Disease	atrial natriuretic peptide activity after exercise;GAD
Disease	lipid metabolism;GAD
Disease	obesity;GAD
Disease	progressive renal damage;GAD
Disease	Breast cancer;FunDO
Disease	Stomach cancer;FunDO
Disease	sleep apnea;GAD
Disease	Parkinson disease;FunDO
Disease	Embryoma;FunDO
Disease	vascular disease;GAD
Disease	Chronic simple glaucoma;FunDO
Disease	Gaucher disease;GAD
Disease	VISION;GAD
Disease	nephropathy in other diseases;GAD
Disease	Systemic scleroderma;FunDO
Disease	nephropathy;GAD
Disease	chronic obstructive pulmonary disease;GAD
Disease	Asthma;GAD
Disease	blood pressure;GAD
Disease	Proteinuria;FunDO
Disease	Sarcoidosis;FunDO
Disease	Alzheimer's disease;FunDO
Disease	arterial wall changes;GAD
Disease	CHEMDEPENDENCY;GAD
Disease	endurance performance;GAD
Disease	cardiovascular risk factors;GAD
Disease	Leukoaraiosis;GAD
Disease	Familial Mediterranean fever;FunDO
Disease	Myocardial Infarction;GAD
Disease	Stroke;GAD
Disease	higher blood pressure after hospitalization in normotensi;GAD
Disease	the extent of exercise-induced left ventricular growth in endurance athletes;GAD
Disease	Endometriosis;FunDO
Disease	NEUROLOGICAL;GAD
Disease	angiotensin-converting enzyme inhibitors;GAD
Disease	sarcoidosis.;GAD
Disease	coronary artery plaque calcification;GAD
Disease	Fatigue Syndrome, Chronic;GAD
Disease	Testicular dysfunction;FunDO
Disease	malignant vascular injury;GAD
Disease	Angiotensin-converting enzyme activity;GAD
Disease	Severe acute respiratory syndrome;FunDO
Disease	cardiomyopathy;GAD
Disease	muscle testing;GAD
Disease	failure of renoprotective therapy;GAD
Disease	RENAL;GAD
Disease	Lupus;GAD
Disease	Metabolic syndrome X;FunDO
External Links
Links to Entrez Gene	1636
Links to all GeneRIF Items	1636
Links to iHOP	1636
Sequence Information
Nucleotide Sequence	>1636 : length: 3921 atgggggccgcctcgggccgccgggggccggggctgctgctgccgctgccgctgctgttg ctgctgccgccgcagcccgccctggcgttggaccccgggctgcagcccggcaacttttct gctgacgaggccggggcgcagctcttcgcgcagagctacaactccagcgccgaacaggtg ctgttccagagcgtggccgccagctgggcgcacgacaccaacatcaccgcggagaatgca aggcgccaggaggaagcagccctgctcagccaggagtttgcggaggcctggggccagaag gccaaggagctgtatgaaccgatctggcagaacttcacggacccgcagctgcgcaggatc atcggagctgtgcgcaccctgggctctgccaacctgcccctggctaagcggcagcagtac aacgccctgctaagcaacatgagcaggatctactccaccgccaaggtctgcctccccaac aagactgccacctgctggtccctggacccagatctcaccaacatcctggcttcctcgcga agctacgccatgctcctgtttgcctgggagggctggcacaacgctgcgggcatcccgctg aaaccgctgtacgaggatttcactgccctcagcaatgaagcctacaagcaggacggcttc acagacacgggggcctactggcgctcctggtacaactcccccaccttcgaggacgatctg gaacacctctaccaacagctagagcccctctacctgaacctccatgccttcgtccgccgc gcactgcatcgccgatacggagacagatacatcaacctcaggggacccatccctgctcat ctgctgggagacatgtgggcccagagctgggaaaacatctacgacatggtggtgcctttc ccagacaagcccaacctcgatgtcaccagtactatgctgcagcagggctggaacgccacg cacatgttccgggtggcagaggagttcttcacctccctggagctctcccccatgcctccc gagttctgggaagggtcgatgctggagaagccggccgacgggcgggaagtggtgtgccac gcctcggcttgggacttctacaacaggaaagacttcaggatcaagcagtgcacacgggtc acgatggaccagctctccacagtgcaccatgagatgggccatatacagtactacctgcag tacaaggatctgcccgtctccctgcgtcggggggccaaccccggcttccatgaggccatt ggggacgtgctggcgctctcggtctccactcctgaacatctgcacaaaatcggcctgctg gaccgtgtcaccaatgacacggaaagtgacatcaattacttgctaaaaatggcactggaa aaaattgccttcctgccctttggctacttggtggaccagtggcgctggggggtctttagt gggcgtacccccccttcccgctacaacttcgactggtggtatcttcgaaccaagtatcag gggatctgtcctcctgttacccgaaacgaaacccactttgatgctggagctaagtttcat gttccaaatgtgacaccatacatcaggtactttgtgagttttgtcctgcagttccagttc catgaagccctgtgcaaggaggcaggctatgagggcccactgcaccagtgtgacatctac cggtccaccaaggcaggggccaagctccggaaggtgctgcaggctggctcctccaggccc tggcaggaggtgctgaaggacatggtcggcttagatgccctggatgcccagccgctgctc aagtacttccagccagtcacccagtggctgcaggagcagaaccagcagaacggcgaggtc ctgggctggcccgagtaccagtggcacccgccgttgcctgacaactacccggagggcata gacctggtgactgatgaggctgaggccagcaagtttgtggaggaatatgaccggacatcc caggtggtgtggaacgagtatgccgaggccaactggaactacaacaccaacatcaccaca gagaccagcaagattctgctgcagaagaacatgcaaatagccaaccacaccctgaagtac ggcacccaggccaggaagtttgatgtgaaccagttgcagaacaccactatcaagcggatc ataaagaaggttcaggacctagaacgggcagcactgcctgcccaggagctggaggagtac aacaagatcctgttggatatggaaaccacctacagcgtggccactgtgtgccacccgaat ggcagctgcctgcagctcgagccagatctgacgaatgtgatggccacgtcccggaaatat gaagacctgttatgggcatgggagggctggcgagacaaggcggggagagccatcctccag ttttacccgaaatacgtggaactcatcaaccaggctgcccggctcaatggctatgtagat gcaggggactcgtggaggtctatgtacgagacaccatccctggagcaagacctggagcgg ctcttccaggagctgcagccactctacctcaacctgcatgcctacgtgcgccgggccctg caccgtcactacggggcccagcacatcaacctggaggggcccattcctgctcacctgctg gggaacatgtgggcgcagacctggtccaacatctatgacttggtggtgcccttcccttca gccccctcgatggacaccacagaggctatgctaaagcagggctggacgcccaggaggatg tttaaggaggctgatgatttcttcacctccctggggctgctgcccgtgcctcctgagttc tggaacaagtcgatgctggagaagccaaccgacgggcgggaggtggtctgccacgcctcg gcctgggacttctacaacggcaaggacttccggatcaagcagtgcaccaccgtgaacttg gaggacctggtggtggcccaccacgaaatgggccacatccagtatttcatgcagtacaaa gacttacctgtggccttgagggagggtgccaaccccggcttccatgaggccattggggac gtgctagccctctcagtgtctacgcccaagcacctgcacagtctcaacctgctgagcagt gagggtggcagcgacgagcatgacatcaactttctgatgaagatggcccttgacaagatc gcctttatccccttcagctacctcgtcgatcagtggcgctggagggtatttgatggaagc atcaccaaggagaactataaccaggagtggtggagcctcaggctgaagtaccagggcctc tgccccccagtgcccaggactcaaggtgactttgacccaggggccaagttccacattcct tctagcgtgccttacatcaggtactttgtcagcttcatcatccagttccagttccacgag gcactgtgccaggcagctggccacacgggccccctgcacaagtgtgacatctaccagtcc aaggaggccgggcagcgcctggcgaccgccatgaagctgggcttcagtaggccgtggccg gaagccatgcagctgatcacgggccagcccaacatgagcgcctcggccatgttgagctac ttcaagccgctgctggactggctccgcacggagaacgagctgcatggggagaagctgggc tggccgcagtacaactggacgccgaactccgctcgctcagaagggcccctcccagacagc ggccgcgtcagcttcctgggcctggacctggatgcgcagcaggcccgcgtgggccagtgg ctgctgctcttcctgggcatcgccctgctggtagccaccctgggcctcagccagcggctc ttcagcatccgccaccgcagcctccaccggcactcccacgggccccagttcggctccgag gtggagctgagacactcctga
Protein Sequence	>1636 : length: 1306 MGAASGRRGPGLLLPLPLLLLLPPQPALALDPGLQPGNFSADEAGAQLFAQSYNSSAEQV LFQSVAASWAHDTNITAENARRQEEAALLSQEFAEAWGQKAKELYEPIWQNFTDPQLRRI IGAVRTLGSANLPLAKRQQYNALLSNMSRIYSTAKVCLPNKTATCWSLDPDLTNILASSR SYAMLLFAWEGWHNAAGIPLKPLYEDFTALSNEAYKQDGFTDTGAYWRSWYNSPTFEDDL EHLYQQLEPLYLNLHAFVRRALHRRYGDRYINLRGPIPAHLLGDMWAQSWENIYDMVVPF PDKPNLDVTSTMLQQGWNATHMFRVAEEFFTSLELSPMPPEFWEGSMLEKPADGREVVCH ASAWDFYNRKDFRIKQCTRVTMDQLSTVHHEMGHIQYYLQYKDLPVSLRRGANPGFHEAI GDVLALSVSTPEHLHKIGLLDRVTNDTESDINYLLKMALEKIAFLPFGYLVDQWRWGVFS GRTPPSRYNFDWWYLRTKYQGICPPVTRNETHFDAGAKFHVPNVTPYIRYFVSFVLQFQF HEALCKEAGYEGPLHQCDIYRSTKAGAKLRKVLQAGSSRPWQEVLKDMVGLDALDAQPLL KYFQPVTQWLQEQNQQNGEVLGWPEYQWHPPLPDNYPEGIDLVTDEAEASKFVEEYDRTS QVVWNEYAEANWNYNTNITTETSKILLQKNMQIANHTLKYGTQARKFDVNQLQNTTIKRI IKKVQDLERAALPAQELEEYNKILLDMETTYSVATVCHPNGSCLQLEPDLTNVMATSRKY EDLLWAWEGWRDKAGRAILQFYPKYVELINQAARLNGYVDAGDSWRSMYETPSLEQDLER LFQELQPLYLNLHAYVRRALHRHYGAQHINLEGPIPAHLLGNMWAQTWSNIYDLVVPFPS APSMDTTEAMLKQGWTPRRMFKEADDFFTSLGLLPVPPEFWNKSMLEKPTDGREVVCHAS AWDFYNGKDFRIKQCTTVNLEDLVVAHHEMGHIQYFMQYKDLPVALREGANPGFHEAIGD VLALSVSTPKHLHSLNLLSSEGGSDEHDINFLMKMALDKIAFIPFSYLVDQWRWRVFDGS ITKENYNQEWWSLRLKYQGLCPPVPRTQGDFDPGAKFHIPSSVPYIRYFVSFIIQFQFHE ALCQAAGHTGPLHKCDIYQSKEAGQRLATAMKLGFSRPWPEAMQLITGQPNMSASAMLSY FKPLLDWLRTENELHGEKLGWPQYNWTPNSARSEGPLPDSGRVSFLGLDLDAQQARVGQW LLLFLGIALLVATLGLSQRLFSIRHRSLHRHSHGPQFGSEVELRHS